These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
405 related articles for article (PubMed ID: 36142848)
21. Diphenyl Diselenide and SARS-CoV-2: Omage FB; Madabeni A; Tucci AR; Nogara PA; Bortoli M; Rosa ADS; Neuza Dos Santos Ferreira V; Teixeira Rocha JB; Miranda MD; Orian L J Chem Inf Model; 2023 Apr; 63(7):2226-2239. PubMed ID: 36952618 [TBL] [Abstract][Full Text] [Related]
22. Discovery of 9,10-dihydrophenanthrene derivatives as SARS-CoV-2 3CL Zhang JW; Xiong Y; Wang F; Zhang FM; Yang X; Lin GQ; Tian P; Ge G; Gao D Eur J Med Chem; 2022 Jan; 228():114030. PubMed ID: 34883292 [TBL] [Abstract][Full Text] [Related]
23. Exploring naphthyl derivatives as SARS-CoV papain-like protease (PLpro) inhibitors and its implications in COVID-19 drug discovery. Amin SA; Ghosh K; Singh S; Qureshi IA; Jha T; Gayen S Mol Divers; 2022 Feb; 26(1):215-228. PubMed ID: 33675510 [TBL] [Abstract][Full Text] [Related]
24. Reactivity and binding mode of disulfiram, its metabolites, and derivatives in SARS-CoV-2 PL Nogara PA; Omage FB; Bolzan GR; Delgado CP; Orian L; Rocha JBT J Mol Model; 2022 Oct; 28(11):354. PubMed ID: 36222962 [TBL] [Abstract][Full Text] [Related]
25. Unravelling lead antiviral phytochemicals for the inhibition of SARS-CoV-2 M Gurung AB; Ali MA; Lee J; Farah MA; Al-Anazi KM Life Sci; 2020 Aug; 255():117831. PubMed ID: 32450166 [TBL] [Abstract][Full Text] [Related]
26. Discovery of unsymmetrical aromatic disulfides as novel inhibitors of SARS-CoV main protease: Chemical synthesis, biological evaluation, molecular docking and 3D-QSAR study. Wang L; Bao BB; Song GQ; Chen C; Zhang XM; Lu W; Wang Z; Cai Y; Li S; Fu S; Song FH; Yang H; Wang JG Eur J Med Chem; 2017 Sep; 137():450-461. PubMed ID: 28624700 [TBL] [Abstract][Full Text] [Related]
27. Non-Toxic Dimeric Peptides Derived from the Bothropstoxin-I Are Potent SARS-CoV-2 and Papain-like Protease Inhibitors. Freire MCLC; Noske GD; Bitencourt NV; Sanches PRS; Santos-Filho NA; Gawriljuk VO; de Souza EP; Nogueira VHR; de Godoy MO; Nakamura AM; Fernandes RS; Godoy AS; Juliano MA; Peres BM; Barbosa CG; Moraes CB; Freitas-Junior LHG; Cilli EM; Guido RVC; Oliva G Molecules; 2021 Aug; 26(16):. PubMed ID: 34443484 [TBL] [Abstract][Full Text] [Related]
28. Mass Spectrometric Assays Reveal Discrepancies in Inhibition Profiles for the SARS-CoV-2 Papain-Like Protease. Brewitz L; Kamps JJAG; Lukacik P; Strain-Damerell C; Zhao Y; Tumber A; Malla TR; Orville AM; Walsh MA; Schofield CJ ChemMedChem; 2022 May; 17(9):e202200016. PubMed ID: 35085423 [TBL] [Abstract][Full Text] [Related]
29. In-silico pharmacophoric and molecular docking-based drug discovery against the Main Protease (Mpro) of SARS-CoV-2, a causative agent COVID-19. Haider Z; Subhani MM; Farooq MA; Ishaq M; Khalid M; Akram MN; Khan RSA; Niazi AK Pak J Pharm Sci; 2020 Nov; 33(6):2697-2705. PubMed ID: 33867348 [TBL] [Abstract][Full Text] [Related]
30. Structure-Based Screening to Discover New Inhibitors for Papain-like Proteinase of SARS-CoV-2: An Jamalan M; Barzegari E; Gholami-Borujeni F J Proteome Res; 2021 Jan; 20(1):1015-1026. PubMed ID: 33350309 [TBL] [Abstract][Full Text] [Related]
31. Molecular Docking and Dynamics Investigations for Identifying Potential Inhibitors of the 3-Chymotrypsin-like Protease of SARS-CoV-2: Repurposing of Approved Pyrimidonic Pharmaceuticals for COVID-19 Treatment. Elzupir AO Molecules; 2021 Dec; 26(24):. PubMed ID: 34946540 [TBL] [Abstract][Full Text] [Related]
32. Determination of potential inhibitors based on isatin derivatives against SARS-CoV-2 main protease (m Badavath VN; Kumar A; Samanta PK; Maji S; Das A; Blum G; Jha A; Sen A J Biomol Struct Dyn; 2022 Apr; 40(7):3110-3128. PubMed ID: 33200681 [TBL] [Abstract][Full Text] [Related]
33. Dual Inhibitors of Main Protease (M Mondal S; Chen Y; Lockbaum GJ; Sen S; Chaudhuri S; Reyes AC; Lee JM; Kaur AN; Sultana N; Cameron MD; Shaffer SA; Schiffer CA; Fitzgerald KA; Thompson PR J Am Chem Soc; 2022 Nov; 144(46):21035-21045. PubMed ID: 36356199 [TBL] [Abstract][Full Text] [Related]
35. Ligand-based and structure-based studies to develop predictive models for SARS-CoV-2 main protease inhibitors through the 3d-qsar.com portal. Proia E; Ragno A; Antonini L; Sabatino M; Mladenovič M; Capobianco R; Ragno R J Comput Aided Mol Des; 2022 Jul; 36(7):483-505. PubMed ID: 35716228 [TBL] [Abstract][Full Text] [Related]
36. Identification of SARS-CoV-2 Main Protease Inhibitors from a Library of Minor Cannabinoids by Biochemical Inhibition Assay and Surface Plasmon Resonance Characterized Binding Affinity. Liu C; Puopolo T; Li H; Cai A; Seeram NP; Ma H Molecules; 2022 Sep; 27(18):. PubMed ID: 36144858 [TBL] [Abstract][Full Text] [Related]
37. Virtual screening of phytoconstituents from miracle herb Siddiqui S; Upadhyay S; Ahmad R; Gupta A; Srivastava A; Trivedi A; Husain I; Ahmad B; Ahamed M; Khan MA J Biomol Struct Dyn; 2022 Jun; 40(9):3928-3948. PubMed ID: 33289456 [TBL] [Abstract][Full Text] [Related]
38. Natural biflavones are potent inhibitors against SARS-CoV-2 papain-like protease. Li L; Ma L; Hu Y; Li X; Yu M; Shang H; Zou Z Phytochemistry; 2022 Jan; 193():112984. PubMed ID: 34757253 [TBL] [Abstract][Full Text] [Related]
39. Computational investigation of benzalacetophenone derivatives against SARS-CoV-2 as potential multi-target bioactive compounds. Khanal P; Patil VS; Bhandare VV; Dwivedi PSR; Shastry CS; Patil BM; Gurav SS; Harish DR; Roy S Comput Biol Med; 2022 Jul; 146():105668. PubMed ID: 35667894 [TBL] [Abstract][Full Text] [Related]
40. Structure-Based Design of a Dual-Targeted Covalent Inhibitor Against Papain-like and Main Proteases of SARS-CoV-2. Yu W; Zhao Y; Ye H; Wu N; Liao Y; Chen N; Li Z; Wan N; Hao H; Yan H; Xiao Y; Lai M J Med Chem; 2022 Dec; 65(24):16252-16267. PubMed ID: 36503248 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]